Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?

Key Points

• Vor Biopharma shares fell 8.2% to about $20.21 in mid-day trading, with volume 59% below the stock’s average daily level.
• Analysts maintain a generally positive outlook: Vor has a “Moderate Buy” consensus rating and an average price target of $43.38, although recent brokerages upgraded their ratings only to “Hold” or kept a neutral view.
• The clinical-stage biotech missed quarterly earnings expectations, reporting an adjusted loss of $0.80 per share versus the expected $0.69 loss. Institutional investors own 97.29% of the stock, while the company continues developing trem-cel, an investigational gene-edited therapy for blood cancers.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) shares fell 8.2% during mid-day trading on Wednesday . The stock traded as low as $20.41 and last traded at $20.2050. Approximately 428,626 shares changed hands during trading, a decline of 59% from the average daily volume of 1,056,572 shares. The stock had previously closed at $22.00.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VOR. Wedbush increased their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Vor Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, September 14th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $43.38.

Vor Biopharma Stock Down 11.9%

The business's 50 day simple moving average is $22.08 and its 200 day simple moving average is $17.77.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). As a group, sell-side analysts anticipate that Vor Biopharma Inc. will post -2.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Large investors have recently modified their holdings of the stock. Fcpm Iii Services B.V. boosted its stake in Vor Biopharma by 852.8% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock worth $47,315,000 after buying an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in shares of Vor Biopharma in the 4th quarter worth about $33,275,000. NEXTBio Capital Management LP purchased a new position in shares of Vor Biopharma during the 4th quarter worth about $13,080,000. Braidwell LP raised its position in Vor Biopharma by 22.8% in the 2nd quarter. Braidwell LP now owns 573,104 shares of the company's stock worth $10,551,000 after purchasing an additional 106,330 shares during the period. Finally, Findell Capital Management LLC bought a new stake in Vor Biopharma in the fourth quarter worth about $3,021,000. Institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor's lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.